Cargando…

Patient-Reported Outcomes as Interradiographic Predictors of Response in Non–Small Cell Lung Cancer

PURPOSE: Minimally invasive biomarkers have been used as important indicators of treatment response and progression in cancers such as prostate and ovarian. Unfortunately, all biomarkers are not prognostic in all cancer types and are often not routinely collected. Patient-reported outcomes (PRO) pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatt, Ambika S., Schabath, Matthew B., Hoogland, Aasha I., Jim, Heather S.L., Brady-Nicholls, Renee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Translational Cancer Mechanisms and Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425729/ https://www.ncbi.nlm.nih.gov/pubmed/37233986 http://dx.doi.org/10.1158/1078-0432.CCR-23-0396

Ejemplares similares

Dynamics of Sequence and Structural Cell-Free DNA Landscapes in Small-Cell Lung Cancer
por: Sivapalan, Lavanya, et al.
Publicado: (2023)

Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair
por: Solta, Anna, et al.
Publicado: (2023)

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer
por: Sabari, Joshua K., et al.
Publicado: (2022)

The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer
por: Choudhury, Noura J., et al.
Publicado: (2023)

Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study
por: Eisner, Joel R., et al.
Publicado: (2023)

Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
por: Majeed, Safa, et al.
Publicado: (2022)

Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset
por: Febres-Aldana, Christopher A., et al.
Publicado: (2022)

Upregulation of Indoleamine 2,3-Dioxygenase 1 in Tumor Cells and Tertiary Lymphoid Structures is a Hallmark of Inflamed Non–Small Cell Lung Cancer
por: Bessede, Alban, et al.
Publicado: (2023)

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer
por: Singer, Christian F., et al.
Publicado: (2022)

Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors
por: Vesely, Clare, et al.
Publicado: (2022)

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
por: Rodriguez-Berriguete, Gonzalo, et al.
Publicado: (2023)

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma
por: Kim, Seok-Young, et al.
Publicado: (2021)

Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1(+) Chemoresistant Lung Cancer Cells
por: Rotolo, Ramona, et al.
Publicado: (2023)

Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
por: Bolton, Kelly L., et al.
Publicado: (2022)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer
por: Cornwell, Abigail C., et al.
Publicado: (2023)

Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features
por: Lefrère, Hanne, et al.
Publicado: (2023)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
por: Christensen, Emil, et al.
Publicado: (2023)

Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021)

Breast Cancer Index Is a Predictive Biomarker of Treatment Benefit and Outcome from Extended Tamoxifen Therapy: Final Analysis of the Trans-aTTom Study
por: Bartlett, John M.S., et al.
Publicado: (2022)

DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
por: Kurani, Hetakshi, et al.
Publicado: (2022)

Preclinical Development of [(211)At]meta- astatobenzylguanidine ([(211)At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma
por: Batra, Vandana, et al.
Publicado: (2022)

PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
por: Stokes, Michael E., et al.
Publicado: (2023)

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer
por: Carter, Jodi M., et al.
Publicado: (2021)

Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception
por: Hernandez, Sharia, et al.
Publicado: (2022)

A Novel Role for DNA-PK in Metabolism by Regulating Glycolysis in Castration-Resistant Prostate Cancer
por: Dylgjeri, Emanuela, et al.
Publicado: (2022)

The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022)

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022)

Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
por: Tang, Zhe, et al.
Publicado: (2021)

Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy
por: Levin, Noam, et al.
Publicado: (2021)

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
por: Ding, Yang-Yang, et al.
Publicado: (2021)

Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming
por: Simonetta, Federico, et al.
Publicado: (2021)

Memory-like Differentiation Enhances NK Cell Responses to Melanoma
por: Marin, Nancy D., et al.
Publicado: (2021)

RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer
por: Koh, Siang-Boon, et al.
Publicado: (2021)

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program
por: Kim, Dae-Hwan, et al.
Publicado: (2021)

Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer
por: Miao, Yu Rebecca, et al.
Publicado: (2021)

Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer
por: Servetto, Alberto, et al.
Publicado: (2021)

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF(V600E)-Mutant Human Glioma
por: Schreck, Karisa C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lbclkae8j4fnavbfu2jrted9cu